New schizophrenia drug aims to fix the 'Thinking Problem' current meds miss
Disease control
Recruiting now
This study is testing whether a newer schizophrenia medication called Xanomeline/Trospium (XT) can improve thinking, memory, and concentration over one year of treatment. It involves 171 adults with schizophrenia who are already stable on their current antipsychotic medication. T…
Phase: PHASE3 • Sponsor: European Group for Research In Schizophrenia • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC